Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray Resnick

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
Medrxiv : the Preprint Server for Health Sciences|May 10, 2023
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trialsJanani S Iyer, Harsha Pokkalla, Charles Biddle-Snead, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
Hepatology (Baltimore, Md.)|February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASHAmaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Nature Medicine|August 7, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseasesJanani S Iyer, Dinkar Juyal, Quang Le, et al.
Nature Medicine|November 4, 2024
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitisHanna Pulaski, Stephen A Harrison, Shraddha S Mehta, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
The Lancet. Oncology|January 17, 2022
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trialHoward P Safran, Kathryn Winter, David H Ilson, et al.
Medrxiv : the Preprint Server for Health Sciences|May 10, 2023
AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trialsJanani S Iyer, Harsha Pokkalla, Charles Biddle-Snead, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 9, 2023
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 StudySanja Dacic, William D Travis, Jennifer M Giltnane, et al.
Hepatology (Baltimore, Md.)|February 11, 2021
A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASHAmaro Taylor-Weiner, Harsha Pokkalla, Ling Han, et al.
Nature Medicine|August 7, 2024
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseasesJanani S Iyer, Dinkar Juyal, Quang Le, et al.
Nature Medicine|November 4, 2024
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitisHanna Pulaski, Stephen A Harrison, Shraddha S Mehta, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
Pageof 3